| Name | Title | Contact Details |
|---|
The Integrated Health and Social Services University Network for West-Central Montreal (CIUSSS West-Central Montreal) is one of the largest health and social services network in the Montreal area, regrouping over 20 establishments in the west end of Montreal and serving a population of nearly 345,000. We are making the difference, one person at a time. CIUSSS West-Central Montreal`s services and programs span the continuum of healthcare, from hospital to community integrated services to residential care. Our 9,000 employees, including 900 doctors, are guided by values of compassion, integrity and commitment to the quality of care. We are proud of our official bilingual status and the culturally rich identities of our sites. On top of clinical activities, research and teaching play an integral part in the CIUSSS West-Central Montreal network.
PREtest Consult is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
USANA Health Sciences’ mission is to develop and provide the highest quality, science-based health products, distributed internationally through network marketing, creating a rewarding financial opportunity for our independent Associates, shareholders, and employees. We’ve got history. Not baggage. We’ve been around since 1992, so we’re experienced (we’ve heard that’s a plus). And we look great for our age. Plus, we have substance to go along with our great looks. We’ve got top-notch manufacturing facilities, our own scientists and research and development team, and the highest standards for our nutritional products. We have an award-winning compensation plan and award-winning products. We don’t like to brag, but we come pretty highly recommended. That’s because we got off on the right foot.
Soda Health is a healthcare technology company focused on building solutions which eliminate health inequities and create a healthier America. Social Determinants of Health (SDOH) have a major impact on health and wellbeing, as well as the cost of care. Our mission is so important, we found a way to work SDOH into our company name.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.